

**FINTEPLA  
(fenfluramine)**

**Pre - PA Allowance**

None

---

**Prior-Approval Requirements**

**Age** 2 years of age and older

**Diagnoses**

Patient must have **ONE** of the following:

1. Seizures associated with Dravet syndrome (DS)
2. Seizures associated with Lennox-Gastaut syndrome (LGS)

**AND ALL** of the following:

1. Patient and prescriber are enrolled in the Fintepla REMS program
2. Patient is currently on **TWO** concomitant anti-seizure medications **OR** has had an inadequate treatment response, intolerance, or contraindication to at least **TWO** of the following medications:
  - a. Clobazam
  - b. Valproate / Valproic acid (i.e., Depakote, Depacon)
  - c. Lamotrigine
  - d. Levetiracetam
  - e. Banzal (rufinamide)
  - f. Topiramate
  - g. Felbamate
  - h. Stiripentol (Dravet syndrome **only**)
3. **NO** dual therapy with monoamine oxidative inhibitors
  - a. Patients currently on monoamine oxidative inhibitors must be tapered off at least 14 days prior to starting Fintepla
4. Prescriber agrees to monitor echocardiogram before initiating therapy, every 6 months while on therapy, and 3 to 6 months after the final dose
5. **NOT** being used for weight loss
6. Prescriber will not exceed the FDA labeled maintenance dose of:
  - a. Patients not on concomitant stiripentol: 26 mg per day
  - b. Patients taking concomitant stiripentol plus clobazam: 17 mg per day



**BlueCross  
BlueShield**

Federal Employee Program.

**FINTEPLA  
(fenfluramine)**

**Prior - Approval Limits**

**Quantity** 1,080 mL per 90 days  
**Duration** 12 months

---

**Prior – Approval *Renewal* Requirements**

**Age** 2 years of age and older

**Diagnoses**

Patient must have **ONE** of the following:

1. Seizures associated with Dravet syndrome (DS)
2. Seizures associated with Lennox-Gastaut syndrome (LGS)

**AND ALL** of the following:

1. Patient experienced a reduction in frequency of seizures
2. **NO** dual therapy with monoamine oxidase inhibitors
3. Prescriber agrees to monitor echocardiogram every 6 months while on therapy, and 3 to 6 months after final dose
4. **NOT** being used for weight loss
5. Prescriber will not exceed the FDA labeled maintenance dose of:
  - a. Patients not on concomitant stiripentol: 26 mg per day
  - b. Patients taking concomitant stiripentol plus clobazam: 17 mg per day

**Prior - Approval *Renewal* Limits**

Same as above